Naoya Aiuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Naoya Aiuchi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Junichi Nakagawa
Department of Pharmacy Hirosaki University Hospital Hirosaki Aomori Japan
2 shared publications - Takenori Niioka
Department of Pharmacy, Hirosaki University Hospital, 53 Hon-cho, Hirosaki, Aomori, 036-8563, Japan.
2 shared publications Hirotake Sakuraba
Department of Gastroenterology and Hematology Hirosaki University Graduate School of Medicine Hirosaki Aomori Japan
1 shared publicationHiroyuki Kayaba
Department of Clinical Laboratory Medicine Hirosaki University Graduate School of Medicine Hirosaki Aomori Japan
1 shared publicationKayo Ueno
Department of Pharmacy Hirosaki University Hospital Hirosaki Aomori Japan
1 shared publicationKazufumi Yamagata
Department of Bioscience and Laboratory Medicine Hirosaki University Graduate School of Health Sciences Hirosaki Japan
1 shared publication
Latest Publications
- Open Access
- 3 January 2023
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 11 (1) , e01048
Impact of solute carrier transporter gene polymorphisms on serum creatinine concentrations in healthy volunteers
In this study, we investigated the impact of single nucleotide polymorphisms in solute carrier (SLC) transporters, that is, SLC22A7 c.1586 + 206A > G, SLC22A2 c.808G > T, SLC22A3 c.1233G > A, SLC47A1 c.922‐158G > A, and SLC47A2 c.‐130G > A, on serum creatinine (SCr) concentrations. This cross‐sectional study included residents who participated as volunteers in a health promotion study. Lifestyle data, blood chemical analysis data, and SLC gene polymorphism information were collected from each participant. Univariate analyses were carried out to determine differences between groups and correlations in SCr. Stepwise multiple regression analysis was performed to confirm the independence of factors that were significantly different in the univariate analyses. In multiple regression analyses, muscle mass, serum cystatin C concentrations, body fat percentage, serum albumin concentrations, and SLC47A2 c.‐130G/G had the highest contribution to SCr concentrations, in that order (standardized regression coefficients = .505, .332, −.234, .123, and .084, respectively). The final model explained 72.2% of the variability in SCr concentrations. The SLC47A2 c.‐130G > A polymorphism may affect creatinine dynamics in the proximal tubules. Further studies are needed to determine the effects of SLC transporter gene polymorphisms on SCr concentrations in patients with various diseases in real‐world clinical settings.
- 3 January 2023
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 11 (1) , e01048
Open AccessImpact of solute carrier transporter gene polymorphisms on serum creatinine concentrations in healthy volunteers
In this study, we investigated the impact of single nucleotide polymorphisms in solute carrier (SLC) transporters, that is, SLC22A7 c.1586 + 206A > G, SLC22A2 c.808G > T, SLC22A3 c.1233G > A, SLC47A1 c.922‐158G > A, and SLC47A2 c.‐130G > A, on serum creatinine (SCr) concentrations. This cross‐sectional study included residents who participated as volunteers in a health promotion study. Lifestyle data, blood chemical analysis data, and SLC gene polymorphism information were collected from each participant. Univariate analyses were carried out to determine differences between groups and correlations in SCr. Stepwise multiple regression analysis was performed to confirm the independence of factors that were significantly different in the univariate analyses. In multiple regression analyses, muscle mass, serum cystatin C concentrations, body fat percentage, serum albumin concentrations, and SLC47A2 c.‐130G/G had the highest contribution to SCr concentrations, in that order (standardized regression coefficients = .505, .332, −.234, .123, and .084, respectively). The final model explained 72.2% of the variability in SCr concentrations. The SLC47A2 c.‐130G > A polymorphism may affect creatinine dynamics in the proximal tubules. Further studies are needed to determine the effects of SLC transporter gene polymorphisms on SCr concentrations in patients with various diseases in real‐world clinical settings.
- Open Access
- 23 February 2022
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 10 (2) , e00935
Impact of polymorphisms of pharmacokinetics‐related genes and the inflammatory response on the metabolism of voriconazole
The effects of inflammatory responses and polymorphisms of the genes encoding cytochrome P450 (CYP) (CYP2C19 and CYP3A5), flavin‐containing monooxygenase 3 (FMO3), pregnane X receptor (NR1I2), constitutive androstane receptor (NR1I3), and CYP oxidoreductase (POR) on the ratio of voriconazole (VRCZ) N‐oxide to VRCZ (VNO/VRCZ) and steady‐state trough concentrations (C0h) of VRCZ were investigated. A total of 56 blood samples were collected from 36 Japanese patients. Results of multiple linear regression analyses demonstrated that the presence of the extensive metabolizer CYP2C19 genotype, the dose per administration, and the presence of the NR1I2 rs3814057 C/C genotype were independent factors influencing the VNO/VRCZ ratio in patients with CRP levels of less than 40 mg/L (standardized regression coefficients (SRC) = 0.448, −0.301, and 0.390, respectively; all p < .05). With regard to the concentration of VRCZ itself, in addition to the above factors, the presence of the NR1I2 rs7643645 G/G and rs3814055 T/T genotypes were found to be independent factors influencing the VRCZ C0h in these patients (SRC = −0.430, 0.424, −0.326, 0.406 and −0.455, respectively; all p < .05). On the contrary, in patients with CRP levels of at least 40 mg/L, no independent factors were found to affect VNO/VRCZ and VRCZ C0h. Inflammatory responses, and CYP2C19 and NR1I2 polymorphisms may be useful information for the individualization of VRCZ dosages.
- 23 February 2022
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 10 (2) , e00935
Open AccessImpact of polymorphisms of pharmacokinetics‐related genes and the inflammatory response on the metabolism of voriconazole
The effects of inflammatory responses and polymorphisms of the genes encoding cytochrome P450 (CYP) (CYP2C19 and CYP3A5), flavin‐containing monooxygenase 3 (FMO3), pregnane X receptor (NR1I2), constitutive androstane receptor (NR1I3), and CYP oxidoreductase (POR) on the ratio of voriconazole (VRCZ) N‐oxide to VRCZ (VNO/VRCZ) and steady‐state trough concentrations (C0h) of VRCZ were investigated. A total of 56 blood samples were collected from 36 Japanese patients. Results of multiple linear regression analyses demonstrated that the presence of the extensive metabolizer CYP2C19 genotype, the dose per administration, and the presence of the NR1I2 rs3814057 C/C genotype were independent factors influencing the VNO/VRCZ ratio in patients with CRP levels of less than 40 mg/L (standardized regression coefficients (SRC) = 0.448, −0.301, and 0.390, respectively; all p < .05). With regard to the concentration of VRCZ itself, in addition to the above factors, the presence of the NR1I2 rs7643645 G/G and rs3814055 T/T genotypes were found to be independent factors influencing the VRCZ C0h in these patients (SRC = −0.430, 0.424, −0.326, 0.406 and −0.455, respectively; all p < .05). On the contrary, in patients with CRP levels of at least 40 mg/L, no independent factors were found to affect VNO/VRCZ and VRCZ C0h. Inflammatory responses, and CYP2C19 and NR1I2 polymorphisms may be useful information for the individualization of VRCZ dosages.